Effect of valsartan on quality of life when added to usual therapy for heart failure: Results from the Valsartan Heart Failure Trial

Giuseppina Majani, Anna Giardini, Cristina Opasich, Robert Glazer, Allen Hester, Gianni Tognoni, Jay N Cohn, Luigi Tavazzi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: The effect on quality of life (QOL) of valsartan administered in addition to prescribed background heart failure therapy was assessed as a secondary endpoint in the Valsartan Heart Failure Trial (Val-HeFT). Methods and Results: QOL was assessed in 3010 patients receiving either valsartan (160 mg twice daily) or placebo in addition to prescribed background therapy (β-blockers or angiotensin-converting enzyme inhibitors), using the Minnesota Living with Heart Failure (MLWHF) questionnaire. Treatment differences were compared at intervals to 36 months after randomization and at endpoint (last observation) using analysis of covariance and repeated measures mixed-effects, and at endpoint using a Mantel-Haenszel chi-squared test. Scores lower than baseline were indicative of improved QOL. Valsartan had a significant beneficial effect on the least-square mean change in overall MLWHF score from baseline to study endpoint (± standard error) (average followup 23.0 months) compared with placebo (0.19 ± 0.47 versus 1.94 ± 0.48; P = .005 respectively). The placebo group was characterized by a deterioration in QOL as the trial progressed. More patients on valsartan reported a clinically meaningful improvement in MLWHF score (a decrease of ≥5 points) than on placebo (34.0% versus 30.2%). Conclusion: Valsartan compared to placebo added to prescribed therapy slows progressive worsening of QOL in patients with heart failure.

Original languageEnglish (US)
Pages (from-to)253-259
Number of pages7
JournalJournal of cardiac failure
Volume11
Issue number4
DOIs
StatePublished - Jan 1 2005

Fingerprint

Valsartan
Heart Failure
Quality of Life
Placebos
Therapeutics
Random Allocation
Least-Squares Analysis
Angiotensin-Converting Enzyme Inhibitors
Observation

Keywords

  • Angiotensin receptor blocker
  • QOL
  • Val-HeFT
  • β-blockers

Cite this

Effect of valsartan on quality of life when added to usual therapy for heart failure : Results from the Valsartan Heart Failure Trial. / Majani, Giuseppina; Giardini, Anna; Opasich, Cristina; Glazer, Robert; Hester, Allen; Tognoni, Gianni; Cohn, Jay N; Tavazzi, Luigi.

In: Journal of cardiac failure, Vol. 11, No. 4, 01.01.2005, p. 253-259.

Research output: Contribution to journalArticle

Majani, Giuseppina ; Giardini, Anna ; Opasich, Cristina ; Glazer, Robert ; Hester, Allen ; Tognoni, Gianni ; Cohn, Jay N ; Tavazzi, Luigi. / Effect of valsartan on quality of life when added to usual therapy for heart failure : Results from the Valsartan Heart Failure Trial. In: Journal of cardiac failure. 2005 ; Vol. 11, No. 4. pp. 253-259.
@article{350069ece46d4ab895a065e78d06240d,
title = "Effect of valsartan on quality of life when added to usual therapy for heart failure: Results from the Valsartan Heart Failure Trial",
abstract = "Background: The effect on quality of life (QOL) of valsartan administered in addition to prescribed background heart failure therapy was assessed as a secondary endpoint in the Valsartan Heart Failure Trial (Val-HeFT). Methods and Results: QOL was assessed in 3010 patients receiving either valsartan (160 mg twice daily) or placebo in addition to prescribed background therapy (β-blockers or angiotensin-converting enzyme inhibitors), using the Minnesota Living with Heart Failure (MLWHF) questionnaire. Treatment differences were compared at intervals to 36 months after randomization and at endpoint (last observation) using analysis of covariance and repeated measures mixed-effects, and at endpoint using a Mantel-Haenszel chi-squared test. Scores lower than baseline were indicative of improved QOL. Valsartan had a significant beneficial effect on the least-square mean change in overall MLWHF score from baseline to study endpoint (± standard error) (average followup 23.0 months) compared with placebo (0.19 ± 0.47 versus 1.94 ± 0.48; P = .005 respectively). The placebo group was characterized by a deterioration in QOL as the trial progressed. More patients on valsartan reported a clinically meaningful improvement in MLWHF score (a decrease of ≥5 points) than on placebo (34.0{\%} versus 30.2{\%}). Conclusion: Valsartan compared to placebo added to prescribed therapy slows progressive worsening of QOL in patients with heart failure.",
keywords = "Angiotensin receptor blocker, QOL, Val-HeFT, β-blockers",
author = "Giuseppina Majani and Anna Giardini and Cristina Opasich and Robert Glazer and Allen Hester and Gianni Tognoni and Cohn, {Jay N} and Luigi Tavazzi",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.cardfail.2004.11.004",
language = "English (US)",
volume = "11",
pages = "253--259",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Effect of valsartan on quality of life when added to usual therapy for heart failure

T2 - Results from the Valsartan Heart Failure Trial

AU - Majani, Giuseppina

AU - Giardini, Anna

AU - Opasich, Cristina

AU - Glazer, Robert

AU - Hester, Allen

AU - Tognoni, Gianni

AU - Cohn, Jay N

AU - Tavazzi, Luigi

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: The effect on quality of life (QOL) of valsartan administered in addition to prescribed background heart failure therapy was assessed as a secondary endpoint in the Valsartan Heart Failure Trial (Val-HeFT). Methods and Results: QOL was assessed in 3010 patients receiving either valsartan (160 mg twice daily) or placebo in addition to prescribed background therapy (β-blockers or angiotensin-converting enzyme inhibitors), using the Minnesota Living with Heart Failure (MLWHF) questionnaire. Treatment differences were compared at intervals to 36 months after randomization and at endpoint (last observation) using analysis of covariance and repeated measures mixed-effects, and at endpoint using a Mantel-Haenszel chi-squared test. Scores lower than baseline were indicative of improved QOL. Valsartan had a significant beneficial effect on the least-square mean change in overall MLWHF score from baseline to study endpoint (± standard error) (average followup 23.0 months) compared with placebo (0.19 ± 0.47 versus 1.94 ± 0.48; P = .005 respectively). The placebo group was characterized by a deterioration in QOL as the trial progressed. More patients on valsartan reported a clinically meaningful improvement in MLWHF score (a decrease of ≥5 points) than on placebo (34.0% versus 30.2%). Conclusion: Valsartan compared to placebo added to prescribed therapy slows progressive worsening of QOL in patients with heart failure.

AB - Background: The effect on quality of life (QOL) of valsartan administered in addition to prescribed background heart failure therapy was assessed as a secondary endpoint in the Valsartan Heart Failure Trial (Val-HeFT). Methods and Results: QOL was assessed in 3010 patients receiving either valsartan (160 mg twice daily) or placebo in addition to prescribed background therapy (β-blockers or angiotensin-converting enzyme inhibitors), using the Minnesota Living with Heart Failure (MLWHF) questionnaire. Treatment differences were compared at intervals to 36 months after randomization and at endpoint (last observation) using analysis of covariance and repeated measures mixed-effects, and at endpoint using a Mantel-Haenszel chi-squared test. Scores lower than baseline were indicative of improved QOL. Valsartan had a significant beneficial effect on the least-square mean change in overall MLWHF score from baseline to study endpoint (± standard error) (average followup 23.0 months) compared with placebo (0.19 ± 0.47 versus 1.94 ± 0.48; P = .005 respectively). The placebo group was characterized by a deterioration in QOL as the trial progressed. More patients on valsartan reported a clinically meaningful improvement in MLWHF score (a decrease of ≥5 points) than on placebo (34.0% versus 30.2%). Conclusion: Valsartan compared to placebo added to prescribed therapy slows progressive worsening of QOL in patients with heart failure.

KW - Angiotensin receptor blocker

KW - QOL

KW - Val-HeFT

KW - β-blockers

UR - http://www.scopus.com/inward/record.url?scp=18144365472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144365472&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2004.11.004

DO - 10.1016/j.cardfail.2004.11.004

M3 - Article

C2 - 15880333

AN - SCOPUS:18144365472

VL - 11

SP - 253

EP - 259

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 4

ER -